JLINX

Accelerating Research to
Transform Human Health

Learn more

About Us

Johnson & Johnson Innovation, JLINX is a multifaceted initiative in Europe designed to identify and nurture early-stage companies who are actively pursuing research with the potential to transform human health.

Accelerating early-stage transformative innovation

We catalyze scientific advances by offering start-ups a spectrum of flexible ways to grow and collaborate across the European life science ecosystem.

Located in a fully dedicated facility on the Janssen Campus in Beerse, Belgium, Johnson & Johnson Innovation, JLINX fosters a creative start-up culture, provides access to select scientific talent and resources on the Janssen Campus and through the Johnson & Johnson Innovation network.

JLINX has a focus on human microbiome research, alongside other areas of innovation in pharmaceuticals and cross-disciplinary healthcare solutions.

Team

Johnson & Johnson Innovation, JLINX is a collaboration between Janssen Pharmaceutica NV and bioqube ventures, which will provide an experienced management team to run the day-to-day operations of JLINX, including managing the investment portfolio and relationships with external venture investors, involvement in identifying and securing new companies, and supporting the overall scale-up of the new initiative.

  • Tom Aelbrecht
    Head of the Janssen Campus Office
  • Debora Dumont
    Managing director of Bioqube Ventures
  • Nico Vandervelpen
    Managing director of Bioqube Ventures

Approach

Johnson & Johnson Innovation, JLINX will provides entrepreneurs with opportunities to share ideas and collaborate with each other while accessing a unique combination of resources including investment, infrastructure, and access to relevant internal and external scientific, technical and business expertise.

Operating at the Nexus of Science and Business

JLINX complements and extends the Johnson & Johnson Innovation network of initiatives to create a unique environment for scientist entrepreneurs to access capital, infrastructure, resources and expertise needed to build their businesses and advance scientific research and development for the benefit of patients.

JLINX accelerates early-stage transformative innovation, including a focus on the human microbiome as well as broader life-science research.

Nurtured Independence

Investment in promising transformative innovation through Johnson & Johnson Innovation, JLINX is venture-based and the Johnson & Johnson Family of Companies will not hold any specific rights to commercialized products by virtue of the JLINX relationship.

Johnson & Johnson Innovation will works closely with Bioqube Ventures, which will provide an experienced incubator management team to run day-to-day operations, including managing the investment portfolio and relationships with external venture investors, involvement in identifying and securing new companies, and supporting the overall scale-up of the new initiative.

Agility with Scale

Our model combines internal expertise with external entrepreneurial skills creating a start-up culture with selected resources, insights and expertise of a global healthcare leader to accelerate breakthroughs.

JLINX Community

bioqube.jpg caelus.jpg octimet.jpg s-biomedic.jpg etherna.jpg

News

  • Caelus Health joins the JLINX Community

    Amsterdam, the Netherlands
    January 26, 2017

    Caelus Health has secured EUR 2.5 million in a Series A investment round, enabling the company to advance its pipeline of microbiota-based products for early intervention in cardio-metabolic disease.

    Caelus Health is one of the first companies fully dedicated to the clinical development of microbiota-based products for early intervention in cardio-metabolic disease. Caelus was founded in 2014 by prof. Max Nieuwdorp (Academic Medical Centre, AMC, Amsterdam) and prof. Willem M. De Vos (Wageningen University), based on the initial work with fecal transplant studies in the AMC. 

  • Octimet Oncology joins the JLINX Community

    Beerse, Belgium
    January 19, 2017

    OCTIMET Oncology NV (OCTIMET), has secured EUR 11.3 million in a Series A investment round, enabling the company to accelerate the development of a clinically de-risked MET kinase inhibitor, as single agent or in combination with standard of care and targeted agents for the treatment of solid cancers.

    OCTIMET was founded in 2016 by Timothy Perera PhD, Ann Meulemans PhD, Paolo Comoglio, MD, PhD and Philip Owen FCA. Headed by Dr. Timothy Perera, OCTIMET has licensed highly selective MET kinase inhibitors from Janssen Pharmaceutica NV and will advance the development of these molecules by employing innovative patient selection and pharmacodynamic biomarker-based approaches, as well as an innovative clinical development strategy, to provide differentiation both within the current treatment paradigms and from competitor agents. 

  • eTheRNA joins the JLINX Community

    December 23, 2016

    Founded in January 2013 as a spin-off of the VUB Laboratory for Molecular and Cellular Therapy (LMCT) headed by Prof K. Thielemans, eTheRNA immunotherapies (Belgium) is a ground-breaking global pioneer in the development of mRNA-based immunotherapies for different cancers and certain infectious diseases.

    eTheRNA is focusing on therapies that prepare and activate the immune system by programming dendritic cells (DC) with synthetic mRNA. For this purpose, eTheRNA continues to develop its proprietary TriMix platform comprising three mRNA molecules that jointly have a boost effect on the activation and maturation of dendritic cells, leading to potent population of both helper T-cells and cytotoxic T-cells. 

Pages

Events

Contact Us

Make the Connection

JLINX is open to receive applications. We look forward to discussing opportunities to collaborate with you.

For general inquiries about JLINX, contact:
JLINX@ITS.JNJ.com

For investment inquiries, contact:
info@bioqubeventures.com

Telephone:
+32 (0) 14-621-500

Download the Johnson & Johnson
JLINX fact sheet.

Accelerators

Close
Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
mail@www.neomed.ca
www.neomed.ca
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.